v3.25.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS      
Cash  
Prepaid expenses and other   9,339 81,223
Due from Sponsor   36,503
Total current assets   45,842 81,223
Cash and Investments held in Trust Account   6,668,522 19,901,169
TOTAL ASSETS   6,714,364 19,982,392
CURRENT LIABILITIES      
Accounts payable   1,030,615 152,005
Loan and Transfer notes payable   465,722 12,384
Subscription Agreement loan   13,760,771
Other current liabilities   358,939 238,939
Total current liabilities   15,616,047 403,328
TOTAL LIABILITIES   15,616,047 403,328
COMMITMENTS AND CONTINGENCIES (Note 9)  
REDEEMABLE ORDINARY SHARES      
Class A ordinary shares subject to possible redemption at redemption value, $0.0001 par value, 577,644 and 1,803,729 shares at redemption value of $11.54 and $ 11.03 per share on December 31, 2024 and 2023, respectively   6,668,522 19,901,169
SHAREHOLDERS’ DEFICIT      
Preference shares; $0.0001 par value,10,000,000 shares authorized, none issued or outstanding  
Additional paid-in capital   8,802,978 10,964,930
Accumulated deficit   (24,373,902) (11,287,754)
Total shareholders’ deficit   (15,570,205) (322,105)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT   6,714,364 19,982,392
Aspire Biopharma Inc [Member]      
CURRENT ASSETS      
Cash   3,633 11,174
Prepaid Expenses   144,356 35,000
Subscriptions Receivable  
Total current assets   147,989 46,174
TOTAL ASSETS   147,989 46,174
CURRENT LIABILITIES      
Accounts payable   310,219 172,773
Loan and Transfer notes payable   1,266,832 360,636
Other current liabilities   111,026 626
Total current liabilities   1,688,077 534,035
TOTAL LIABILITIES   1,688,077 534,035
SHAREHOLDERS’ DEFICIT      
Class A common stock; $0.0001 par value; 490,000,000 shares authorized; 49,525,970 and 27,601,767 issued and outstanding at June 30, 2025 and December 31, 2024, respectively   22,000 22,000
Additional paid-in capital   1,215,113 957,500
Accumulated deficit   (2,777,233) (1,467,361)
Total shareholders’ deficit   (1,540,088) (487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT   147,989 46,174
Parent Company [Member]      
CURRENT ASSETS      
Cash $ 206,233 3,633  
Prepaid expenses and other 783,189 144,356  
Total current assets 989,422 147,989  
TOTAL ASSETS 989,422 147,989  
CURRENT LIABILITIES      
Accounts payable 1,351,639 310,219  
Accrued expenses 378,181  
Subscription Agreement loan 2,025,344  
Convertible Note 3,617,508  
Loan and Transfer notes payable 499,214  
Other current liabilities 111,026  
Notes payable – related party 1,331,356 1,266,832  
Total current liabilities 10,556,922 1,688,077  
Forward purchase agreement liability 49,285  
TOTAL LIABILITIES 10,606,207 1,688,077  
COMMITMENTS AND CONTINGENCIES (Note 9)  
SHAREHOLDERS’ DEFICIT      
Preference shares; $0.0001 par value,10,000,000 shares authorized, none issued or outstanding  
Class A common stock; $0.0001 par value; 490,000,000 shares authorized; 49,525,970 and 27,601,767 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4,953 2,760  
Additional paid-in capital 11,078,116 1,234,385  
Accumulated deficit (20,699,854) (2,777,233)  
Total shareholders’ deficit (9,616,785) (1,540,088) (487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT 989,422 147,989  
Parent Company [Member] | Affiliates [Member]      
CURRENT LIABILITIES      
Other current liabilities 353,679  
Parent Company [Member] | Related Party [Member]      
CURRENT LIABILITIES      
Notes payable – related party 1,331,357 1,266,832  
Promissory note fee – related party $ 1,000,000  
Common Class A [Member]      
SHAREHOLDERS’ DEFICIT      
Class A common stock; $0.0001 par value; 490,000,000 shares authorized; 49,525,970 and 27,601,767 issued and outstanding at June 30, 2025 and December 31, 2024, respectively   719 719
Common Class B [Member]      
SHAREHOLDERS’ DEFICIT      
Class A common stock; $0.0001 par value; 490,000,000 shares authorized; 49,525,970 and 27,601,767 issued and outstanding at June 30, 2025 and December 31, 2024, respectively  
Series A Preferred Stock [Member] | Aspire Biopharma Inc [Member]      
SHAREHOLDERS’ DEFICIT      
Preference shares; $0.0001 par value,10,000,000 shares authorized, none issued or outstanding   $ 32